Moxetumomab pasudotox

Innate Pharma Reports First Half 2022 Financial Results and Business Update

Retrieved on: 
Thursday, September 15, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cetuximab, Termination, Trial of the century, COVID-19, Sarbanes, Risk, Net, Research, Supervisory board, Sarbanes–Oxley Act, Company, Acquisition, Review, Investment, SAS, Depreciation, Intangibles, AstraZeneca, Nasdaq, IAS, Accounting, BNP Paribas, Risk factor, Insurance, Collection, Board of directors, AMF, Rale, Classification, Federal Executive Boards, Lawyer, Transition, Mission statement, Lithium, Pharmaceutical industry, Health insurance, Renewable energy, Cryptocurrency, Online gambling, Moxetumomab pasudotox, Monalizumab, Sanofi

The fall in other expenses of 0.8m mainly results from non recurring provisions for liabilities and charges booked in the 1st half of 2021 reversed in 1st half of 2022.

Key Points: 
  • The fall in other expenses of 0.8m mainly results from non recurring provisions for liabilities and charges booked in the 1st half of 2021 reversed in 1st half of 2022.
  • The Company has not made any investments in tangible, intangible or significant financial assets during the first half of 2022 and 2021.
  • Furthermore, the conflict triggered by Russia's invasion of Ukraine on February 24, 2022 had no significant direct or indirect consequences on the Company's interim consolidated financial statements for the first half of 2022.
  • An update of that risk is presented in note G) of the half-year management review as of June 30, 2022.

Worldwide Cancer Biological Toxins Drug Industry to 2026 - Featuring Angimmune, Astrazeneca and Sanofi Among Others

Retrieved on: 
Friday, February 5, 2021
Moxetumomab pasudotox, Cancer vaccine, Cancer, Treatment of cancer, Drugs, Health

DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026 Report Highlights:
    Cancer Biological Toxins Clinical Trials: >70 Drugs in Pipeline
    Global Cancer Biological Toxins Expected Market Opportunity: > US$ 200 Million
    Cancer Biological Toxins Clinical Trial Insight by Phase, Status, Cancer & Country
    Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)
    While hundreds of other cancer therapies are failing to stake their applications in treating cancer patients, cancer biological toxin therapy is caught in the middle to get recognized as an offering that is unimaginable.
  • Immune Checkpoint Inhibitor Therapy
    4.1.2 Cancer Biological Toxin Therapy Vs. Immunotherapy Monoclonal Antibodies
    4.1.3 Cancer Biological Toxins Therapy Market Vs. Cancer Vaccine Market
    4.2.1 Cancer Biological Toxin Therapy Market Vs.
  • Radiation Therapy for Cancer Treatment
    4.2.3 Cancer Biological Toxin Therapy Vs. Surgical Procedure for Cancer Treatment

Global Cancer Biological Toxins Drug Market (2020 to 2026) - Opportunity, Drug Sales & Clinical Trials Insight - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 3, 2021
Pharmaceutical, Health, Oncology, Orphan drugs, Moxetumomab pasudotox, Cancer, Health, Clinical medicine, Antineoplastic drugs

Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026 Report Highlights:

Key Points: 
  • Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026 Report Highlights:
    Cancer Biological Toxins Clinical Trials: >70 Drugs in Pipeline
    Global Cancer Biological Toxins Expected Market Opportunity: > US$ 200 Million
    Cancer Biological Toxins Clinical Trial Insight by Phase, Status, Cancer & Country
    Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)
    While hundreds of other cancer therapies are failing to stake their applications in treating cancer patients, cancer biological toxin therapy is caught in the middle to get recognized as an offering that is unimaginable.
  • The market since its emergence has remained ahead with respect to the overall survival rate it is delivering as well as solving the entire healthcare problems related with cancer development and progression.
  • Traditionally, the cancer biological toxin market is prone to deliver and provide value in terms of complete eradication of the cancer cells by performing splendid research and development activities.
  • This resulted in the foundational shift in the entire cancer therapeutics industry and thus, the emergence of therapy that involves toxins isolated from prokaryotes for killing the cancer cells.

Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca

Retrieved on: 
Friday, December 11, 2020
Companies, Orphan drugs, Moxetumomab pasudotox, Drugs, AstraZeneca, Hairy cell leukemia, Business

Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio

Key Points: 
  • Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio
    MARSEILLE, France, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) today announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca1.
  • Innate licensed the US and EU rights to AstraZenecas FDA-approved Lumoxiti for certain patients with relapsed or refractory hairy cell leukemia in October 2018 .
  • The companies will develop a transition plan, including costs and transfer of the US marketing authorization and distribution of Lumoxiti back to AstraZeneca in 2021.
  • Since in-licensing Lumoxiti from AstraZeneca, we have been committed to delivering this medicine to patients and healthcare professionals in the US, and moving towards commercialization in the EU.

BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1

Retrieved on: 
Wednesday, June 10, 2020
Oncology, Health, Chemicals, Plastics, Manufacturing, Clinical trials, Pharmaceutical, Biotechnology, RTT, Medicine, Clinical medicine, Cancer, Acute lymphocytic leukemia, 75th United States Congress, National Cancer Institute, Leukemia, Acute lymphoblastic leukemia, Bryostatin, Moxetumomab pasudotox, Cancer Trials Support Unit, AMRI, BryoLogyx

Neurotrope has been developing bryostatin-1 under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).

Key Points: 
  • Neurotrope has been developing bryostatin-1 under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).
  • These two agreements with Neurotrope will accelerate our drive to clinical trials to demonstrate proof-of-concept in patients.
  • The agreements should position BryoLogyx to begin clinical trials with the NCI in late 2020.
  • Under the first agreement, Neurotrope will transfer to BryoLogyx the right to develop bryostatin1 for the potential treatment of CD22+ B-cell acute lymphoblastic leukemia (ALL).

The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia

Retrieved on: 
Thursday, January 2, 2020
Cancer treatments, Drugs, Clinical medicine, Antibody-drug conjugates, Monoclonal antibodies, Hairy cell leukemia, Lymphocytic leukemia, Moxetumomab pasudotox, Leukemia, Breakthrough therapy, Loncastuximab tesirine, Camidanlumab tesirine

The EMA filing is based on the final analysis of the pivotal Phase III trial of Lumoxiti, presented at ASH 2019*.

Key Points: 
  • The EMA filing is based on the final analysis of the pivotal Phase III trial of Lumoxiti, presented at ASH 2019*.
  • These data showed that 36 percent (29/80) of the relapsed or refractory hairy cell leukemia patients achieved durable complete response, defined as a CR with a hematological remission maintained for at least 180 days.
  • The EMA filling acceptance follows the U.S. Food and Drug Administration (FDA) approval of Lumoxiti in September 2018.
  • Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.

Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019

Retrieved on: 
Sunday, December 8, 2019
Companies, Monoclonal antibodies, AstraZeneca, Södertälje Municipality, Life sciences, Drugs, Moxetumomab pasudotox

Treatment-related grade 3/4 AEs were reported in 24 patients (30%) and treatment-related serious AEs in 14 patients (18%).

Key Points: 
  • Treatment-related grade 3/4 AEs were reported in 24 patients (30%) and treatment-related serious AEs in 14 patients (18%).
  • Innate Pharmas commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018.
  • Innate Pharmas broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
  • Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting

Retrieved on: 
Thursday, November 7, 2019
Monoclonal antibodies, Moxetumomab pasudotox, Companies, Euronext, Drugs, AstraZeneca, Life sciences

Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) will share new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab pasudotox) at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, December 7-10.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) will share new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab pasudotox) at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, December 7-10.
  • Innate Pharmas commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018.
  • Innate Pharmas broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
  • Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma announces the exercise in full of the option granted to the underwriters of its global offering and Nasdaq global select market listing to purchase 1,875,000 additional ADSs

Retrieved on: 
Friday, October 18, 2019
Euronext, Companies, Monoclonal antibodies, AstraZeneca, Moxetumomab pasudotox, Drugs, Life sciences

This trading halt will continue until the closing of Euronext Paris today and trading will resume at the opening of Euronext Paris at 9:00 AM CEST on October 18, 2019.

Key Points: 
  • This trading halt will continue until the closing of Euronext Paris today and trading will resume at the opening of Euronext Paris at 9:00 AM CEST on October 18, 2019.
  • Innates commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018.
  • Innates broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
  • Innate is a public company listed in compartment B of Euronexts regulated market in Paris (Euronext: IPH - ISIN: FR0010331421).

Hairy Cell Leukemia (HCL): Market Insights, Epidemiology and Forecast to 2028 - Key Players are Working Robustly on New Therapies with Novel Mechanism of Action - ResearchAndMarkets.com

Retrieved on: 
Friday, February 15, 2019
Health, Pharmaceutical, Monoclonal antibodies, Lymphocytic leukemia, Moxetumomab pasudotox, RTT, Hairy cell leukemia, Organ systems, Leukemia, HCL, Medical specialties, Medicine

The "Hairy Cell Leukemia (HCL) - Market Insights, Epidemiology and Market Forecast-2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hairy Cell Leukemia (HCL) - Market Insights, Epidemiology and Market Forecast-2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this research, the incident population of Hairy Cell Leukemia (HCL) was estimated to be 2,378 [7MM] in 2018.
  • Lumoxiti (moxetumomab pasudotox-tdfk) developed by AstraZeneca is the first in class therapy approved for the treatment of Hairy Cell Leukemia.
  • According to this research, the global market of Hairy Cell Leukemia (HCL) was estimated to be USD 48.12 million in 2018.